The tweet was deleted by the author.
But we saved everything 🙂.
Neurogene Inc. is presenting new findings supporting the therapeutic rationale for intracerebroventricular (ICV) delivery in CNS-targeted gene therapy at the ASGCT2026 conference.
The company’s poster, numbered 1359, details encouraging preclinical data focused on this innovative approach to gene therapy within the central nervous system. Interested attendees can review the poster or access additional information via links provided by Neurogene Inc.
Neurogene previously announced plans to present on ICV delivery for CNS-targeted gene therapy at an earlier ASGCT meeting, according to a company statement. The company has also seen recent leadership changes, appointing Christy Shafer as Chief Commercial Officer and adding Christine Mikail to its board of directors, as detailed in a prior update. These developments come as Neurogene continues to pursue advances in gene therapy for CNS disorders.